WHAT IS CLAIMED IS:

1. A compound according to formula (I):



(I)

or a stereoisomer, tautomer, pharmaceutically acceptable salt thereof, wherein:

ring A is C_{3-6} carbocycle;

ring B is 4- to 7-membered heterocycle containing carbon atoms and 0-3 additional heteroatoms selected from the group consisting of N, NR^6, O, and $S(O)_p$; optionally, ring B forms a fused ring or spiro ring with a 4- to 7-membered heterocycle containing carbon atoms and 1-3 heteroatoms selected from the group consisting of NR^6, O, and $S(O)_p$; ring B, including the fused ring or spiro ring is substituted with 1-3 R^5;

L is selected from the group consisting of: $-CHR^{10}CHR^{10}-$, $-CR^{10}=CR^{10}-$, $-C\equiv C-$, $-CHR^{10}NH-$, $-NHCHR^{10}-$, $-SCH_2-$, $-CH_2S-$, $-SO_2CH_2-$, $-CH_2SO_2-$, $-NHCH_2-$, and $-CH_2NH-$;

R^1, at each occurrence, is selected from the group consisting of: H, halo, C_{1-6} alkyl, C_{1-4} alkoxy, C_{1-4} alkylthio, OH, SH, CHF_2, CF_3, OCF_3, CN, NH_2, COC_{1-4} alkyl, $CO_2(C_{1-4}$ alkyl), $-CH_2CO_2H$, $-CH_2CO_2(C_{1-4}$ alkyl), $-CH_2NH_2$, $-CONH_2$, $-CONH(C_{1-4}$ alkyl), $-NHCO(C_{1-4}$ alkyl), $-NHCO_2(C_{1-4}$ alkyl), $-NHSO_2(C_{1-4}$ alkyl), and $-SO_2NH_2$, and $-C(=NH)NH_2$;

R^2 is selected from the group consisting of: H, halo, CN, OH, C_{1-6} alkyl, C_{1-4} alkoxy, C_{1-6}haloalkyl, C_{1-6}haloalkoxy, $CO(C_{1-4}$ alkyl), $CONH_2$, CO_2H, CH_2NH_2, and a 5- to 7-membered heterocycle comprising carbon atoms and 1-4 heteroatoms selected from N, NR^c, O, and $S(O)_p$, wherein said heterocycle is substituted with 0-2 R^{2a};

R^{2a}, at each occurrence, is selected from the group consisting of: H, halo, C_{1-4} alkyl, -CH_2OH, C_{1-4} alkoxy, OH, CF_3, OCF_3, CN, NH_2, CO_2H, $CO_2(C_{1-4}$ alkyl), $CO(C_{1-4}$ alkyl), -$CONH_2$, -CH_2OH, -CH_2OC_{1-4}alkyl, -CH_2NH_2-, $CONH(C_{1-4}$ alkyl), -$CON(C_{1-4}$ alkyl$)_2$, -$SO_2(C_{1-4}$ alkyl), -SO_2NH_2, -$SO_2NH(C_{1-4}$ alkyl), and -$SO_2N(C_{1-4}$ alkyl$)_2$;

R^3 is selected from the group consisting of: C_{1-6} alkyl substituted with 1-3 R^{3a}, -$(CH_2)_n$-C_{3-10} carbocycle substituted with 0-3 R^{3a} or -$(CH_2)_n$-5-10 membered heterocycle containing carbon atoms and 1-4 heteroatoms selected from the group consisting of N, NR^7, O, and $S(O)_p$; wherein said heterocycle is substituted with 0-3 R^{3a};

R^{3a}, at each occurrence, is selected from the group consisting of: =O, halo, C_{1-4} alkyl, OH, C_{1-4} alkoxy, CN, NH_2, CO_2H, $CO_2(C_{1-4}$ alkyl), $CONH_2$, $CONH(C_{1-6}$ alkyl), $CON(C_{1-4}$ alkyl$)_2$, -$CONH$-C_{1-4} alkylene-$CO_2(C_{1-4}$ alkyl), -$CONHCO_2C_{1-4}$ alkyl, -$CONH$-C_{1-4} alkylene-$NHCO(C_{1-4}$ alkyl), -$CONH$-C_{1-4} alkylene-$CONH_2$, -$NHCOC_{1-4}$ alkyl, -$NHCO_2(C_{1-4}$ alkyl), -C_{1-4} alkylene-$NHCO_2C_{1-4}$ alkyl, R^f, $CONHR^f$, and -CO_2R^f;

R^4, at each occurrence, is selected from the group consisting of: H, halo and C_{1-4} alkyl;

R^5, at each occurrence, is selected from the group consisting of: H, =O, halo, C_{1-4} alkyl, OH, CN, NH_2, -$N(C_{1-4}$ alkyl$)_2$, NO_2, C_{1-4} alkoxy, -$OCO(C_{1-4}$ alkyl), -O-C_{1-4} alkylene-$O(C_{1-4}$ alkyl), -O-C_{1-4} alkylene-$N(C_{1-4}$ alkyl$)_2$, -CO_2H, -$CO_2(C_{1-4}$ alkyl), -$CONH_2$, -$(CH_2)_2CONH_2$, -$CONR^9(C_{1-4}$ alkyl), -$CONR^9$-C_{1-4} alkylene-$O(C_{1-4}$ alkyl), -$CON(C_{1-4}$ alkyl$)_2$, -$CONR^9$-C_{1-4} alkylene-$N(C_{1-4}$ alkyl$)_2$, -$CON(C_{1-4}$ alkyl)-C_{1-4} alkylene-$O(C_{1-4}$ alkyl), -$CONR^9$-C_{1-4} alkylene-$CO_2(C_{1-4}$ alkyl), -NR^9COC_{1-4} alkyl, -$NR^9CO_2C_{1-4}$ alkyl, -$NR^9CONH(C_{1-4}$ alkyl), -NR^9CONR^9-C_{1-4} alkylene-CO_2C_{1-4} alkyl, -NR^9-C_{1-4} alkylene-$N(C_{1-4}$ alkyl$)_2$, R^8, -OR^8, -O-C_{1-4} alkylene-R^8, -COR^8, -CO_2R^8, -$CONR^9R^8$, -NR^9COR^8, -$NR^9CO_2R^8$, and -$NR^9CON\ R^9R^8$;

R^6 is selected from the group consisting of: H, C_{1-4} alkyl, -$CO_2(C_{1-4}$ alkyl), -$CO(C_{1-4}$ alkyl), -$CONH_2$, -CO-C_{1-4} alkylene-$N(C_{1-4}$ alkyl$)_2$, -$(CH_2)_2N(C_{1-4}$ alkyl$)_2$, -$CONR^9(C_{1-4}$ alkyl), -$CONR^9$-C_{1-4} alkylene-$O(C_{1-4}$ alkyl), -$CONR^9$-C_{1-4} alkylene-$N(C_{1-4}$ alkyl$)_2$, -

$CONR^9$-C_{1-4} alkylene-$CO_2(C_{1-4}$ alkyl), -$CON(C_{1-4}$ alkyl$)_2$, R^8, -COR^8, -CO_2R^8, and -$CONR^9R^8$;

R^7, at each occurrence, is selected from the group consisting of: H, C_{1-4} alkyl, COC_{1-4} alkyl, $CO_2(C_{1-4}$ alkyl), CO_2Bn, -CONH-C_{1-4} alkylene-CO_2C_{1-4} alkyl, phenyl, benzyl, and -CO_2-C_{1-4} alkylene-aryl;

R^8, at each occurrence, is selected from the group consisting of: -$(CH_2)_n$-C_{3-10} carbocycle substituted with 0-3 R^e and -$(CH_2)_n$-5-10 membered heterocycle containing carbon atoms and 1-4 heteroatoms selected from the group consisting of N, NR^d, O, and $S(O)_p$; wherein said carbocycle and heterocycle are optionally substituted with =O;

R^9, at each occurrence, is selected from the group consisting of: H and C_{1-4}alkyl;

R^{10}, at each occurrence, is selected from the group consisting of: H, halo, OH, and C_{1-4} alkyl;

R^c is, independently at each occurrence, selected from the group consisting of: H, C_{1-4} alkyl, COC_{1-4} alkyl, CO_2C_{1-4} alkyl, and CO_2Bn;

R^d is, independently at each occurrence, selected from the group consisting of: H, C_{1-4} alkyl, $CO(C_{1-4}$ alkyl), $COCF_3$, $CO_2(C_{1-4}$ alkyl), -CONH-C_{1-4} alkylene-CO_2C_{1-4} alkyl, CO_2Bn, R^f, and $CONHR^f$;

R^e is, independently at each occurrence, selected from the group consisting of: =O, halo, C_{1-4} alkyl, C_{1-4} alkoxy, OCF_3, NH_2, NO_2, $N(C_{1-4}$ alkyl$)_2$, $CO(C_{1-4}$ alkyl), $CO(C_{1-4}$ haloalkyl), $CO_2(C_{1-4}$ alkyl), $CONH_2$, -$CONH(C_{1-4}$ alkyl), -CONHPh, -$CON(C_{1-4}$ alkyl$)_2$, -CONH-C_{1-4} alkylene-$O(C_{1-4}$ alkyl), -CONH-C_{1-4} alkylene-$N(C_{1-4}$ alkyl$)_2$, -CONH-C_{1-4} alkylene-$CO_2(C_{1-4}$ alkyl), -$NHCO_2(C_{1-4}$ alkyl), R^f, COR^f, CO_2R^f and $CONHR^f$;

R^f is, independently at each occurrence, selected from the group consisting of: -$(CH_2)_n$-C_{3-6} cycloalkyl, -$(CH_2)_n$-phenyl, and -$(CH_2)_n$-5- to 6- membered heterocycle containing carbon atoms and 1-4 heteroatoms selected from the group consisting of N, NR^c, O, and $S(O)_p$; wherein each ring moiety is substituted with 0-2 R^g;

R^g is, independently at each occurrence, selected from the group consisting of: =O, halo, C_{1-4} alkyl, OH, C_{1-4} alkoxy, and $NHCO(C_{1-4}$ alkyl);

n, at each occurrence, is selected from 0, 1, 2, 3, and 4; and

p, at each occurrence, is selected from 0, 1, and 2.

2. The compound of claim 1, or a stereoisomer, tautomer, pharmaceutically acceptable salt thereof, wherein:

ring A is C_{3-6} carbocycle;

ring B is 4- to 7-membered heterocycle containing carbon atoms and 0-3 additional heteroatoms selected from the group consisting of N, NR^6, O, and $S(O)_p$; optionally, ring B forms a fused ring or spiro ring with a 4- to 7-membered heterocycle containing carbon atoms and 1-3 heteroatoms selected from the group consisting of NR^6, O, and $S(O)_p$; ring B, including the fused ring or spiro ring is substituted with 1-3 R^5;

L is selected from the group consisting of: a bond, $-CHR^{10}CHR^{10}-$, $-CR^{10}=CR^{10}-$, and $-C\equiv C-$;

R^1, at each occurrence, is selected from the group consisting of: H, halo, C_{1-2} alkyl, $-O(C_{1-4}$ alkyl), CN, $-CH_2NH_2$, and $-C(=NH)NH_2$;

R^2 is independently selected from the group consisting of: H, halo, CN, OH C_{1-6} alkyl, C_{1-4} alkoxy, C_{1-6}haloalkyl, C_{1-6}haloalkoxy, $CO(C_{1-4}$ alkyl), and a 5- to 7-membered heterocycle comprising carbon atoms and 1-4 heteroatoms selected from N, NH, $N(C_{1-4}$ alkyl), O, and $S(O)_p$, wherein said heterocycle is substituted with 1-2 R^{2a};

R^{2a}, at each occurrence, is selected from the group consisting of: H, halo, C_{1-4} alkyl, CO_2H, $-CO_2(C_{1-4}$ alkyl), $-CONH_2$, $-CH_2OH$, $-CH_2OC_{1-4}$alkyl, and $-CH_2NH_2$;

R^3 is selected from the group consisting of: C_{1-6} alkyl substituted with 1-3 R^{3a}, C_{3-10} carbocycle substituted with 1-3 R^{3a}, and 5-10 membered heterocycle containing carbon atoms and 1-4 heteroatoms selected from the group consisting of N, NR^7, O, and $S(O)_p$; wherein said heterocycle is substituted with 1-3 R^{3a};

R^{3a}, at each occurrence, is selected from the group consisting of: H, halo, C_{1-4} alkyl, -OH, C_{1-4} alkoxy, -CN, $-NH_2$, ,$-NH(C_{1-4}$ alkyl), $-N(C_{1-4}$ alkyl)$_2$, $-CO_2H$, $-CH_2CO_2H$, $-CO_2(C_{1-4}$ alkyl), $-CO_2$-C_{1-4} alkylene-$O(C_{1-4}$ alkyl), $-CO_2$-C_{1-4} alkylene-$N(C_{1-4}$ alkyl)$_2$, $-CONH_2$, $-CONH(C_{1-6}$ alkyl), $-CON(C_{1-4}$ alkyl)$_2$, -CONH-C_{1-4} alkylene-$CO_2(C_{1-4}$ alkyl), $-CONHCO_2C_{1-4}$ alkyl, -CONH-C_{1-4} alkylene-$NHCO(C_{1-4}$ alkyl), -CONH-C_{1-4} alkylene-$CONH_2$, $-NHCOC_{1-4}$ alkyl, $-NHCO_2(C_{1-4}$ alkyl), R^f, $-CONHR^f$, and $-CO_2R^f$;

R^4, at each occurrence, is selected from the group consisting of: H, halo, and C_{1-4} alkyl;

R^5, at each occurrence, is selected from the group consisting of: H, =O, halo, C_{1-4} alkyl, OH, CN, NH_2, -N(C_{1-4} alkyl)$_2$, NO_2, C_{1-4} alkoxy, -OCO(C_{1-4} alkyl), -O-C_{1-4} alkylene-O(C_{1-4} alkyl), -O-C_{1-4} alkylene-N(C_{1-4} alkyl)$_2$, -CO_2H, -CO_2(C_{1-4} alkyl), -$CONH_2$, -$(CH_2)_2CONH_2$, -$CONR^9$(C_{1-4} alkyl), -$CONR^9$-C_{1-4} alkylene-O(C_{1-4} alkyl), -CON(C_{1-4} alkyl)$_2$, -$CONR^9$-C_{1-4} alkylene-N(C_{1-4} alkyl)$_2$, -CON(C_{1-4} alkyl)-C_{1-4} alkylene-O(C_{1-4} alkyl), -$CONR^9$-C_{1-4} alkylene-CO_2(C_{1-4} alkyl), -NR^9COC_{1-4} alkyl, -$NR^9CO_2C_{1-4}$ alkyl, -NR^9CONH(C_{1-4} alkyl), -NR^9CONR^9-C_{1-4} alkylene-CO_2C_{1-4} alkyl, -NR^9-C_{1-4} alkylene-N(C_{1-4} alkyl)$_2$, R^8, -OR^8, -O-C_{1-4} alkylene-R^8, -COR^8, -CO_2R^8, -$CONR^9R^8$, -NR^9COR^8, -$NR^9CO_2R^8$, and -NR^9CON R^9R^8;

R^6 is selected from the group consisting of: H, C_{1-4} alkyl, -CO_2(C_{1-4} alkyl), -CO(C_{1-4} alkyl), -$CONH_2$, -CO-C_{1-4} alkylene-N(C_{1-4} alkyl)$_2$, -$(CH_2)_2$N(C_{1-4} alkyl)$_2$, -$CONR^9$(C_{1-4} alkyl), -$CONR^9$-C_{1-4} alkylene-O(C_{1-4} alkyl), -$CONR^9$-C_{1-4} alkylene-N(C_{1-4} alkyl)$_2$, -$CONR^9$-C_{1-4} alkylene-CO_2(C_{1-4} alkyl), -CON(C_{1-4} alkyl)$_2$, R^8, -COR^8, -CO_2R^8, and -$CONR^9R^8$;

R^7, at each occurrence, is selected from the group consisting of: H, C_{1-4} alkyl, -CO_2(C_{1-4} alkyl), and -CO_2-C_{1-4} alkylene-aryl;

R^8, at each occurrence, is selected from the group consisting of: -$(CH_2)_n$-C_{3-10} carbocycle and -$(CH_2)_n$-5-10 membered heterocycle containing carbon atoms and 1-4 heteroatoms selected from the group consisting of N, NH, N(C_{1-4} alkyl), O, and $S(O)_p$; wherein said carbocycle and heterocycle are optionally substituted with =O;

R^9, at each occurrence, is selected from the group consisting of: H and C_{1-4}alkyl;

R^{10}, at each occurrence, is selected from the group consisting of: H and F;

R^f, at each occurrence, is selected from the group consisting of: -$(CH_2)_n$-C_{3-6} cycloalkyl, -$(CH_2)_n$-phenyl, and -$(CH_2)_n$-5- to 6- membered heterocycle; wherein each ring moiety is substituted with 0-2 R^g;

R^g is, independently at each occurrence, selected from the group consisting of: =O, halo, C_{1-4} alkyl, OH, C_{1-4} alkoxy, and NHCO(C_{1-4} alkyl);

n, at each occurrence, is selected from 0, 1, 2, 3, and 4; and

p, at each occurrence, is selected from 0, 1, and 2.

3. The compound of claim 2 having formula (II):



(II)

or a stereoisomer, tautomer, pharmaceutically acceptable salt thereof, wherein:

W is selected from the group consisting of $CR^{5b}R^{5c}$, O, $S(O)_p$, and NR^6;

R^{4a}, R^{4b}, R^{4c}, and R^{4d} are independently selected from the group consisting of: H, F, and C_{1-4} alkyl;

R^{5a} is selected from the group consisting of: H and =O;

R^{5b} and R^{5c} are independently selected from the group consisting of: H, halo, C_{1-4} alkyl, OH, CN, NH_2, $-N(C_{1-4}$ alkyl$)_2$, C_{1-4} alkoxy, $-OCO-C_{1-4}$ alkyl, $-O-C_{1-4}$alkylene-$N(C_{1-4}$ alkyl$)_2$, $-O-C_{1-4}$alkylene-$O(C_{1-4}$ alkyl), $-CO_2H$, $-CO_2(C_{1-4}$ alkyl), $-CONH_2$, $-CONR^9(C_{1-4}$ alkyl), $-CON(C_{1-4}$ alkyl$)_2$, R^8, $-OR^8$, $-COR^8$, and $-CO_2R^8$;

optionally, R^{5b} and R^{5c} together with the carbon atom to which they are attached form a 4-7 membered heterocyclic ring containing carbon atoms and 1-4 heteroatoms selected from the group consisting of N, NR^6, O, and $S(O)_p$; wherein said heterocycle is unsubstituted or substituted with =O.

q, at each occurrence, is selected from 0, 1, and 2; and

r, at each occurrence, is selected from 0, 1, and 2.

4. The compound of claim 3 having formula (III):



(III)

or a stereoisomer, tautomer, pharmaceutically acceptable salt thereof, wherein:

R^{1a} is selected from the group consisting of: H, halo, C_{1-2} alkyl, and methoxy; R^{1b} is selected from the group consisting of: H and halo;

R^2 is independently selected from the group consisting of: H, F, CN, OH, C_{1-4} alkoxy, $-CHF_2$, $-CF_3$, $-CH_2NH_2$, $-OCHF_2$, $-CO(C_{1-4}$ alkyl), $-CONH_2$, -COOH, triazole substituted with R^{2a}, and tetrazole substituted with R^{2a};

R^3 is selected from the group consisting of: phenyl substituted with 1-2 R^{3a}, C_{3-6} cycloalkyl substituted with 1-2 R^{3a}, heterocycle substituted with 1-2 R^{3a}; wherein said heterocycle is selected from the group consisting of: piperidinyl, pyridyl, indolyl, and indazolyl.

5. A compound of claim 4 having formula (IV):



(IV)

or a stereoisomer, tautomer, pharmaceutically acceptable salt thereof, wherein:

 is selected from the group consisting of:  , 

 ,  ,  ,  ,  ,  , and



R^3 is selected from the group consisting of: phenyl substituted with 1-2 R^{3a}, pyridyl substituted with 1-2 R^{3a}, C_{3-6} cycloalkyl substituted with 1-2 R^{3a},  , and

 ;

R^7 is selected from the group consisting of: H and C_{1-4} alkyl.

6. The compound of claim 5 having formula (V):



(V)

or a stereoisomer, tautomer, pharmaceutically acceptable salt thereof, wherein:

R^3 is selected from the group consisting of: phenyl substituted with 1-2 R^{3a} and pyridyl substituted with 1-2 R^{3a};


is selected from the group consisting of:



R^{3a}, at each occurrence, is selected from the group consisting of: H, halo, C_{1-4} alkyl, OH, C_{1-4} alkoxy, CN, NH_2, $-CO_2H$, $-CH_2CO_2H$, $-CO_2(C_{1-4}$ alkyl), $-CO_2(CH_2)_{1-2}O(C_{1-4}$ alkyl), $-CO_2(CH_2)_{1-2}CON(C_{1-4}$ alkyl)$_2$, $-CONH_2$, $CONH(C_{1-4}$ alkyl), $-CON(C_{1-4}$ alkyl)$_2$; , $-NHCO_2(C_{1-4}$ alkyl), R^8, $-CONHR^8$, and $-CO_2R^8$

R^{5b} and R^{5c} are independently selected from the group consisting of: H, C_{1-4} alkyl, OH, CN, NH_2, $-N(C_{1-4}$ alkyl)$_2$, C_{1-4} alkoxy, $-OCO-C_{1-4}$ alkyl, $-CO_2H$, $-CO_2(C_{1-4}$ alkyl), $-CONH_2$, $-CONR^9(C_{1-4}$ alkyl), $-CON(C_{1-4}$ alkyl)$_2$, R^8, $-OR^8$, $-COR^8$, and $-CO_2R^8$;

optionally, R^{5b} and R^{5c} together with the carbon atom to which they are both attached form a 5-6 membered heterocyclic ring containing carbon atoms and 1-4 heteroatoms selected from the group consisting of N, NR^6, O, and $S(O)_p$; wherein said heterocycle is unsubstituted or substituted with =O; and

R^6 is selected from the group consisting of: H, C_{1-4} alkyl, $-CO_2(C_{1-4}$ alkyl), $-CO(C_{1-4}$ alkyl), $-CO-C_{1-4}$ alkylene-$N(C_{1-4}$ alkyl)$_2$, $-CONH_2$, $-(CH_2)_2N(C_{1-4}$ alkyl)$_2$, $-CONH(C_{1-4}$ alkyl), $-CONH-C_{1-4}$ alkylene-$O(C_{1-4}$ alkyl), $-CONH-C_{1-4}$ alkylene-$N(C_{1-4}$ alkyl)$_2$, $-CONH-C_{1-4}$ alkylene-$CO_2(C_{1-4}$ alkyl), $-CONH(C_{1-4}$ alkyl), $-CON(C_{1-4}$ alkyl)$_2$, R^8, $-COR^8$, and $-CO_2R^8$.

7. The compound of claim 6, having formula (VI):



(VI)

or a stereoisomer, tautomer, pharmaceutically acceptable salt thereof, wherein:

R^{1b} is independently selected from the group consisting of: H and F;

R^{3a} is selected from the group consisting of: H, halo, CN, CO_2H, $-CO_2(C_{1-4}$ alkyl), $-CO_2(CH_2)_{1-2}O(C_{1-4}$ alkyl), $-CO_2(CH_2)_{1-2}CON(C_{1-4}$ alkyl$)_2$, $-CONH_2$, $-CONH(C_{1-4}$ alkyl), $-NHCO_2(C_{1-4}$ alkyl), $-CO_2(C_{3-6}$ cycloalkyl), $-CO_2(CH_2)_{1-2}Ph$, and $-CO_2(CH_2)_{1-2}$triazole.

8. The compound of claim 7, wherein:



is selected from the group consisting of :,



,



, ,





,



,



,



,



,



,



,



,



,







,



,



,



,



R^{3a} is independently selected from the group consisting of: H, F, Cl, CN, CO_2H, -CO_2Me, -CO_2Et , -CO_2(*i*-Pr), -CO_2(*t*-Bu), -CO_2(*n*-Bu), -CO_2(*i*-Bu), -$CO_2(CH_2)_2OMe$, -$CO_2CH_2CON(Me)_2$, -$NHCO_2Me$, -CO_2CH_2(phenyl), -CO_2(C_{3-6} cycloalkyl), and -$CO_2(CH_2)_2$-triazole; and

R^6 is selected from the group consisting of: H, C_{1-4} alkyl, -CO_2(C_{1-4} alkyl), -CO(C_{1-4} alkyl), -$COCH_2N$(C_{1-4} alkyl)$_2$, -$(CH_2)_{1-2}N$(C_{1-4} alkyl)$_2$, -CONH(C_{1-4} alkyl), -CONH-C_{1-4} alkylene-O(C_{1-4} alkyl), -CONH-C_{1-4} alkylene-N(C_{1-4} alkyl)$_2$, -CONH-C_{1-4} alkylene-CO_2(C_{1-4} alkyl), -CH_2Ph, and -CO_2-C_{1-4} alkylene-Ph.

9. The compound of claim 3 having Formula (VII):



(VII)

or a stereoisomer, tautomer, pharmaceutically acceptable salt thereof, wherein:

R^{1b} is selected from the group consisting of: H and F;

 is selected from the group consisting of:  ,  , and ;

R^2 is selected from the group consisting of: H, F, CN, COMe, OH, OMe, $OCHF_2$, CHF_2, CF_3, and tetrazole;

R^3 is selected from the group consisting of: phenyl substituted with 1-2 R^{3a}, cyclohexyl,  , and  ;

R^{3a} is independently selected from the group consisting of: H, F, Cl, CN, CO_2H, -CH_2CO_2H, CO_2Me, -CO_2Et, -CO_2(*i*-Pr), -CO_2(*t*-Bu), -CO_2(*n*-Bu), -CO_2(*i*-Bu), -$CO_2(CH_2)_2OMe$, -$CO_2CH_2CON(Me)_2$, -$NHCO_2Me$, -$CO_2(CH_2)_2$-triazole, and -CO_2(cyclopentyl);

R^{4c} and R^{4d} are independently selected from the group consisting of: H and Me;

R^{5b} and R^{5c} are, independently selected from the group consisting of: H, F, Me, Et, i-propyl, CN, OH, -OMe, -CO_2Me, -CO_2Et, -$CON(Me)_2$, NH_2, -$N(Me)_2$, -$O(CH_2)N(Me)_2$, -$O(CH_2)OMe$,  ,  , and  ;

R^6 is selected from the group consisting of: H, Me, -CO_2Me, -CO_2(t-butyl), -COMe, -CONHMe, -$CONH(CH_2)_2CO_2Et$, $CONH(CH_2)_2N(Me)_2$, -CO_2CH_2Ph, -$(CH_2)_2N(Me)_2$, and -CH_2Ph;

R^7 is selected from the group consisting of: H and Me;

q, at each occurrence, is selected from 0, 1, and 2; and

r, at each occurrence, is selected from 0, 1, and 2.

10. The compound of claim 9 having Formula (VIII):



(VIII)

or a stereoisomer, tautomer, pharmaceutically acceptable salt thereof, wherein:

R^2 is selected from the group consisting of: H, F, CN, COMe, OH, OMe, $OCHF_2$, CHF_2, CF_3, and tetrazole;

R^{3a} is selected from the group consisting of: H, F, Cl, CN, CO_2H, - CH_2CO_2H, CO_2Me, -CO_2Et, -CO_2(*i*-Pr), -CO_2(*t*-Bu), -CO_2(*n*-Bu), -CO_2(*i*-Bu), - and $NHCO_2Me$;

R^6 is selected from the group consisting of: H, Me, -CO_2Me, -CO_2(t-butyl), -COMe, and –CONHMe;

q is 1or 2; and

r is 1 or 2.

11. The compound of claim 1 having formula (IX):



(IX)

or a stereoisomer, tautomer, pharmaceutically acceptable salt thereof, wherein:

R^{1a} is selected from the group consisting of: H, Cl, C_{1-2} alkyl, and methoxy;

R^{1b} is selected from the group consisting of: H and F;

R^6 is selected from the group consisting of: H, C_{1-4} alkyl, -CO(C_{1-4} alkyl), CO_2H, -CO_2(C_{1-4} alkyl), -$CO(CH_2)_{0-2}NH(C_{1-4}$ alkyl), and -$CO(CH_2)_{0-2}N(C_{1-4}$ alkyl)$_2$; and

R^{3a} is selected from the group consisting of: H, F, Cl, CN, CO_2H, -CO_2Et, and -CO_2(*t*-Bu).

12. The compound of claim 1, wherein:

ring B is heteroaryl or bridged heterocycle, each containing carbon atoms and 0-2 additional heteroatoms selected from the group consisting of N, NH, O, and $S(O)_p$, and each substituted with 1-3 R^5;

R^2 is selected from the group consisting of: H, F, CN, -CO(C_{1-4} alkyl), OH, -O(C_{1-4} alkyl), -$OCHF_2$, -CHF_2, -CF_3, triazole, and tetrazole, wherein said triazole and tetrazole are substituted with 0-2 R^{2a}; and

R^5, at each occurrence, is selected from the group consisting of: H, =O, halo, C_{1-4} alkyl, OH, CN, NH_2, -N(C_{1-4} alkyl)$_2$, C_{1-4} alkoxy, -CO_2H, -CO_2(C_{1-4} alkyl), -$CONH_2$, -$CONR^9$(C_{1-4} alkyl), -CON(C_{1-4} alkyl)$_2$, R^8, and -COR^8.

13. A pharmaceutical composition, comprising: a pharmaceutically acceptable carrier and a therapeutically effective amount of a compound of any one of claims 1-12.

14. Use of a therapeutically effective amount of a compound of any one of claims 1-12 or a pharmaceutically acceptable salt or solvate form thereof in the manufacture of a medicament for treating a thromboembolic or an inflammatory disorder.

15. A use according to claim 14, wherein the thromboembolic disorder is selected from the group consisting of arterial cardiovascular thromboembolic disorders, venous cardiovascular thromboembolic disorders, and thromboembolic disorders in the chambers of the heart.

16. A use according to claim 14, wherein the thromboembolic disorder is selected from unstable angina, an acute coronary syndrome, atrial fibrillation, first myocardial infarction, recurrent myocardial infarction, ischemic sudden death, transient ischemic attack, stroke, atherosclerosis, peripheral occlusive arterial disease, venous thrombosis, deep vein thrombosis, thrombophlebitis, arterial embolism, coronary arterial thrombosis, cerebral arterial thrombosis, cerebral embolism, kidney embolism, pulmonary embolism, and thrombosis resulting from (a) prosthetic valves or other implants, (b) indwelling catheters, (c) stents, (d) cardiopulmonary bypass, (e) hemodialysis, or (f) other procedures in which blood is exposed to an artificial surface that promotes thrombosis.

17. A compound having the structure:



or a pharmaceutically acceptable salt thereof.

Claims

1. A compound according to formula (I):



(I)

or a stereoisomer, tautomer, pharmaceutically acceptable salt or solvate thereof, wherein:

ring A is C_{3-6} carbocycle;

ring B is 4- to 7-membered heterocycle containing carbon atoms and 0-3 additional heteroatoms selected from the group consisting of N, NR^6, O, and $S(O)_p$; optionally, ring B forms a fused ring or spiro ring with a 4- to 7-membered heterocycle containing carbon atoms and 1-3 heteroatoms selected from the group consisting of NR^6, O, and $S(O)_p$; ring B, including the fused ring or spiro ring is substituted with 1-3 R^5;

L is selected from the group consisting of: $-CHR^{10}CHR^{10}-$, $-CR^{10}=CR^{10}-$, $-C\equiv C-$, $-CHR^{10}NH-$, $-NHCHR^{10}-$, $-SCH_2-$, $-CH_2S-$, $-SO_2CH_2-$, $-CH_2SO_2-$, $-NHCH_2-$, and $-CH_2NH-$;

R^1, at each occurrence, is selected from the group consisting of: H, halo, C_{1-6} alkyl, C_{1-4} alkoxy, C_{1-4} alkylthio, OH, SH, CHF_2, CF_3, OCF_3, CN, NH_2, COC_{1-4} alkyl, $CO_2(C_{1-4}$ alkyl), $-CH_2CO_2H$, $-CH_2CO_2(C_{1-4}$ alkyl), $-CH_2NH_2$, $-CONH_2$, $-CONH(C_{1-4}$ alkyl), $-NHCO(C_{1-4}$ alkyl), $-NHCO_2(C_{1-4}$ alkyl), $-NHSO_2(C_{1-4}$ alkyl), and $-SO_2NH_2$, and $-C(=NH)NH_2$;

R^2 is selected from the group consisting of: H, halo, CN, OH, C_{1-6} alkyl, C_{1-4} alkoxy, C_{1-6}haloalkyl, C_{1-6}haloalkoxy, $CO(C_{1-4}$ alkyl), $CONH_2$, CO_2H, CH_2NH_2, and a 5- to 7-membered heterocycle comprising carbon atoms and 1-4

heteroatoms selected from N, NR^c, O, and $S(O)_p$, wherein said heterocycle is substituted with 0-2 R^{2a};

R^{2a}, at each occurrence, is selected from the group consisting of: H, halo, C_{1-4} alkyl, C_{1-4} alkoxy, OH, CF_3, OCF_3, CN, NH_2, CO_2H, $CO_2(C_{1-4}$ alkyl), $CO(C_{1-4}$ alkyl), $-CONH_2$, $-CH_2OH$, $-CH_2OC_{1-4}$alkyl, $-CH_2NH_2$-, $CONH(C_{1-4}$ alkyl), $-CON(C_{1-4}$ alkyl$)_2$, $-SO_2(C_{1-4}$ alkyl), $-SO_2NH_2$, $-SO_2NH(C_{1-4}$ alkyl), and $-SO_2N(C_{1-4}$ alkyl$)_2$;

R^3 is selected from the group consisting of: C_{1-6} alkyl substituted with 1-3 R^{3a}, $-(CH_2)_n$-C_{3-10} carbocycle substituted with 0-3 R^{3a} or $-(CH_2)_n$-5-10 membered heterocycle containing carbon atoms and 1-4 heteroatoms selected from the group consisting of N, NR^7, O, and $S(O)_p$; wherein said heterocycle is substituted with 0-3 R^{3a};

R^{3a}, at each occurrence, is selected from the group consisting of: =O, halo, C_{1-4} alkyl, OH, C_{1-4} alkoxy, CN, NH_2, CO_2H, $CO_2(C_{1-4}$ alkyl), $CONH_2$, $CONH(C_{1-6}$ alkyl), $CON(C_{1-4}$ alkyl$)_2$, $-CONH$-C_{1-4} alkylene-$CO_2(C_{1-4}$ alkyl), $-CONHCO_2C_{1-4}$ alkyl, $-CONH$-C_{1-4} alkylene-$NHCO(C_{1-4}$ alkyl), $-CONH$-C_{1-4} alkylene-$CONH_2$, $-NHCOC_{1-4}$ alkyl, $-NHCO_2(C_{1-4}$ alkyl), $-C_{1-4}$ alkylene-$NHCO_2C_{1-4}$ alkyl, R^f, $CONHR^f$, and $-CO_2R^f$;

R^4, at each occurrence, is selected from the group consisting of: H, halo and C_{1-4} alkyl;

R^5, at each occurrence, is selected from the group consisting of: H, =O, halo, C_{1-4} alkyl, OH, CN, NH_2, $-N(C_{1-4}$ alkyl$)_2$, NO_2, C_{1-4} alkoxy, $-OCO(C_{1-4}$ alkyl), $-O$-C_{1-4} alkylene-$O(C_{1-4}$ alkyl), $-O$-C_{1-4} alkylene-$N(C_{1-4}$ alkyl$)_2$, $-CO_2H$, $-CO_2(C_{1-4}$ alkyl), $-CONH_2$, $-(CH_2)_2CONH_2$, $-CONR^9(C_{1-4}$ alkyl), $-CONR^9$-C_{1-4} alkylene-$O(C_{1-4}$ alkyl), $-CON(C_{1-4}$ alkyl$)_2$, $-CONR^9$-C_{1-4} alkylene-$N(C_{1-4}$ alkyl$)_2$, $-CON(C_{1-4}$ alkyl)-C_{1-4} alkylene-$O(C_{1-4}$ alkyl), $-CONR^9$-C_{1-4} alkylene-$CO_2(C_{1-4}$ alkyl), $-NR^9COC_{1-4}$ alkyl, $-NR^9CO_2C_{1-4}$ alkyl, $-NR^9CONH(C_{1-4}$ alkyl), $-NR^9CONR^9$-C_{1-4} alkylene-CO_2C_{1-4} alkyl, $-NR^9$-C_{1-4} alkylene-$N(C_{1-4}$ alkyl$)_2$, R^8, $-OR^8$, $-O$-C_{1-4} alkylene-R^8, $-COR^8$, $-CO_2R^8$, $-CONR^9R^8$, $-NR^9COR^8$, $-NR^9CO_2R^8$, and $-NR^9CON\ R^9R^8$;

R^6 is selected from the group consisting of: H, C_{1-4} alkyl, $-CO_2(C_{1-4}$ alkyl),

-CO(C_{1-4} alkyl), -$CONH_2$, -CO-C_{1-4} alkylene-N(C_{1-4} alkyl)$_2$, -$(CH_2)_2$N(C_{1-4} alkyl)$_2$, -$CONR^9$(C_{1-4} alkyl), -$CONR^9$-C_{1-4} alkylene-O(C_{1-4} alkyl), -$CONR^9$-C_{1-4} alkylene-N(C_{1-4} alkyl)$_2$, -$CONR^9$-C_{1-4} alkylene-CO_2(C_{1-4} alkyl), -CON(C_{1-4} alkyl)$_2$, R^8, -COR^8, -CO_2R^8, and -$CONR^9R^8$;

R^7, at each occurrence, is selected from the group consisting of: H, C_{1-4} alkyl, COC_{1-4} alkyl, CO_2(C_{1-4} alkyl), CO_2Bn, -CONH-C_{1-4} alkylene-CO_2C_{1-4} alkyl, phenyl, benzyl, and -CO_2-C_{1-4} alkylene-aryl;

R^8, at each occurrence, is selected from the group consisting of: -$(CH_2)_n$-C_{3-10} carbocycle substituted with 0-3 R^e and -$(CH_2)_n$-5-10 membered heterocycle containing carbon atoms and 1-4 heteroatoms selected from the group consisting of N, NR^d, O, and $S(O)_p$; wherein said carbocycle and heterocycle are optionally substituted with =O;

R^9, at each occurrence, is selected from the group consisting of: H and C_{1-4}alkyl;

R^{10}, at each occurrence, is selected from the group consisting of: H, halo, OH, and C_{1-4} alkyl;

R^c is, independently at each occurrence, selected from the group consisting of: H, C_{1-4} alkyl, COC_{1-4} alkyl, CO_2C_{1-4} alkyl, and CO_2Bn;

R^d is, independently at each occurrence, selected from the group consisting of: H, C_{1-4} alkyl, CO(C_{1-4} alkyl), $COCF_3$, CO_2(C_{1-4} alkyl), -CONH-C_{1-4} alkylene-CO_2C_{1-4} alkyl, CO_2Bn, R^f, and $CONHR^f$;

R^e is, independently at each occurrence, selected from the group consisting of: =O, halo, C_{1-4} alkyl, C_{1-4} alkoxy, OCF_3, NH_2, NO_2, N(C_{1-4} alkyl)$_2$, CO(C_{1-4} alkyl), CO(C_{1-4} haloalkyl), CO_2(C_{1-4} alkyl), $CONH_2$, -CONH(C_{1-4} alkyl), -CONHPh, -CON(C_{1-4} alkyl)$_2$, -CONH-C_{1-4} alkylene-O(C_{1-4} alkyl), -CONH-C_{1-4} alkylene-N(C_{1-4} alkyl)$_2$, -CONH-C_{1-4} alkylene-CO_2(C_{1-4} alkyl), -$NHCO_2$(C_{1-4} alkyl), R^f, COR^f, CO_2R^f and $CONHR^f$;

R^f is, independently at each occurrence, selected from the group consisting of:

$-(CH_2)_n-C_{3-6}$ cycloalkyl, $-(CH_2)_n$-phenyl, and $-(CH_2)_n$-5- to 6- membered heterocycle containing carbon atoms and 1-4 heteroatoms selected from the group consisting of N, NR^c, O, and $S(O)_p$; wherein each ring moiety is substituted with 0-2 R^g;

R^g is, independently at each occurrence, selected from the group consisting of: =O, halo, C_{1-4} alkyl, OH, C_{1-4} alkoxy, and $NHCO(C_{1-4}$ alkyl);

n, at each occurrence, is selected from 0, 1, 2, 3, and 4; and

p, at each occurrence, is selected from 0, 1, and 2.

2. The compound of claim 1, or a stereoisomer, tautomer, pharmaceutically acceptable salt thereof, wherein:

ring A is C_{3-6} carbocycle;

ring B is 4- to 7-membered heterocycle containing carbon atoms and 0-3 additional heteroatoms selected from the group consisting of N, NR^6, O, and $S(O)_p$; optionally, ring B forms a fused ring or spiro ring with a 4- to 7-membered heterocycle containing carbon atoms and 1-3 heteroatoms selected from the group consisting of NR^6, O, and $S(O)_p$; ring B, including the fused ring or spiro ring is substituted with 1-3 R^5;

L is selected from the group consisting of: $-CHR^{10}CHR^{10}-$, $-CR^{10}=CR^{10}-$, and -C≡C-;

R^1, at each occurrence, is selected from the group consisting of: H, halo, C_{1-2} alkyl, $-O(C_{1-4}$ alkyl), CN, $-CH_2NH_2$, and $-C(=NH)NH_2$;

R^2 is independently selected from the group consisting of: H, halo, CN, OH C_{1-6} alkyl, C_{1-4} alkoxy, C_{1-6}haloalkyl, C_{1-6}haloalkoxy, $CO(C_{1-4}$ alkyl), and a 5- to 7-membered heterocycle comprising carbon atoms and 1-4 heteroatoms selected from N, NH, $N(C_{1-4}$ alkyl), O, and $S(O)_p$, wherein said heterocycle is substituted with 1-2 R^{2a};

R^{2a}, at each occurrence, is selected from the group consisting of: H, halo, C_{1-4} alkyl, CO_2H, $-CO_2(C_{1-4}$ alkyl), $-CONH_2$, $-CH_2OH$, $-CH_2OC_{1-4}$alkyl, and $-CH_2NH_2$;

R^3 is selected from the group consisting of: C_{1-6} alkyl substituted with 1-3 R^{3a}, C_{3-10} carbocycle substituted with 1-3 R^{3a}, and 5-10 membered heterocycle containing carbon atoms and 1-4 heteroatoms selected from the group consisting of N, NR^7, O, and $S(O)_p$; wherein said heterocycle is substituted with 1-3 R^{3a};

R^{3a}, at each occurrence, is selected from the group consisting of: halo, C_{1-4} alkyl, -OH, C_{1-4} alkoxy, -CN, $-NH_2$, $-CO_2H$, $-CO_2(C_{1-4}$ alkyl), $-CONH_2$, $-CONH(C_{1-6}$ alkyl), $-CON(C_{1-4}$ alkyl$)_2$, $-CONH-C_{1-4}$ alkylene$-CO_2(C_{1-4}$ alkyl), $-CONHCO_2C_{1-4}$ alkyl, $-CONH-C_{1-4}$ alkylene$-NHCO(C_{1-4}$ alkyl), $-CONH-C_{1-4}$ alkylene$-CONH_2$, $-NHCOC_{1-4}$ alkyl, $-NHCO_2(C_{1-4}$ alkyl), R^f, $-CONHR^f$, and $-CO_2R^f$;

R^4, at each occurrence, is selected from the group consisting of: H, halo, and C_{1-4} alkyl;

R^5, at each occurrence, is selected from the group consisting of: H, =O, halo, C_{1-4} alkyl, OH, CN, NH_2, $-N(C_{1-4}$ alkyl$)_2$, NO_2, C_{1-4} alkoxy, $-OCO(C_{1-4}$ alkyl), $-O-C_{1-4}$ alkylene$-O(C_{1-4}$ alkyl), $-O-C_{1-4}$ alkylene$-N(C_{1-4}$ alkyl$)_2$, $-CO_2H$, $-CO_2(C_{1-4}$ alkyl), $-CONH_2$, $-(CH_2)_2CONH_2$, $-CONR^9(C_{1-4}$ alkyl), $-CONR^9-C_{1-4}$ alkylene$-O(C_{1-4}$ alkyl), $-CON(C_{1-4}$ alkyl$)_2$, $-CONR^9-C_{1-4}$ alkylene$-N(C_{1-4}$ alkyl$)_2$, $-CON(C_{1-4}$ alkyl$)-C_{1-4}$ alkylene$-O(C_{1-4}$ alkyl), $-CONR^9-C_{1-4}$ alkylene$-CO_2(C_{1-4}$ alkyl), $-NR^9COC_{1-4}$ alkyl, $-NR^9CO_2C_{1-4}$ alkyl, $-NR^9CONH(C_{1-4}$ alkyl), $-NR^9CONR^9-C_{1-4}$ alkylene$-CO_2C_{1-4}$ alkyl, $-NR^9-C_{1-4}$ alkylene$-N(C_{1-4}$ alkyl$)_2$, R^8, $-OR^8$, $-O-C_{1-4}$ alkylene$-R^8$, $-COR^8$, $-CO_2R^8$, $-CONR^9R^8$, $-NR^9COR^8$, $-NR^9CO_2R^8$, and $-NR^9CON\ R^9R^8$;

R^6 is selected from the group consisting of: H, C_{1-4} alkyl, $-CO_2(C_{1-4}$ alkyl), $-CO(C_{1-4}$ alkyl), $-CONH_2$, $-CO-C_{1-4}$ alkylene$-N(C_{1-4}$ alkyl$)_2$, $-(CH_2)_2N(C_{1-4}$ alkyl$)_2$, $-CONR^9(C_{1-4}$ alkyl), $-CONR^9-C_{1-4}$ alkylene$-O(C_{1-4}$ alkyl), $-CONR^9-C_{1-4}$ alkylene$-N(C_{1-4}$ alkyl$)_2$, $-CONR^9-C_{1-4}$ alkylene$-CO_2(C_{1-4}$ alkyl), $-CON(C_{1-4}$ alkyl$)_2$, R^8, $-COR^8$, $-CO_2R^8$, and $-CONR^9R^8$;

R^7, at each occurrence, is selected from the group consisting of: H, C_{1-4} alkyl, $-CO_2(C_{1-4}$ alkyl), and $-CO_2-C_{1-4}$ alkylene-aryl;

R^8, at each occurrence, is selected from the group consisting of: $-(CH_2)_n-C_{3-10}$ carbocycle and $-(CH_2)_n$-5-10 membered heterocycle containing carbon atoms and 1-4 heteroatoms selected from the group consisting of N, NH, $N(C_{1-4}$ alkyl), O, and $S(O)_p$; wherein said carbocycle and heterocycle are optionally substituted with =O;

R^9, at each occurrence, is selected from the group consisting of: H and C_{1-4}alkyl;

R^{10}, at each occurrence, is selected from the group consisting of: H and F;

R^f, at each occurrence, is selected from the group consisting of: $-(CH_2)_n-C_{3-6}$ cycloalkyl, $-(CH_2)_n$-phenyl, and $-(CH_2)_n$-5- to 6- membered heterocycle; wherein each ring moiety is substituted with 0-2 R^g;

R^g is, independently at each occurrence, selected from the group consisting of: =O, halo, C_{1-4} alkyl, OH, C_{1-4} alkoxy, and $NHCO(C_{1-4}$ alkyl);

n, at each occurrence, is selected from 0, 1, 2, 3, and 4; and

p, at each occurrence, is selected from 0, 1, and 2.

3. The compound of claim 2 having formula (II):



(II)

or a stereoisomer, tautomer, pharmaceutically acceptable salt thereof, wherein:

W is selected from the group consisting of $CR^{5b}R^{5c}$, O, $S(O)_p$, and NR^6;

R^{4a}, R^{4b}, R^{4c}, and R^{4d} are independently selected from the group consisting of: H, F, and C_{1-4} alkyl;

R^{5a} is selected from the group consisting of: H and =O;

R^{5b} and R^{5c} are independently selected from the group consisting of: H, halo, C_{1-4} alkyl, OH, CN, NH_2, $-N(C_{1-4}$ alkyl$)_2$, C_{1-4} alkoxy, $-OCO-C_{1-4}$ alkyl, $-O-C_{1-4}$alkylene-$N(C_{1-4}$ alkyl$)_2$, $-O-C_{1-4}$alkylene-$O(C_{1-4}$ alkyl), $-CO_2H$, $-CO_2(C_{1-4}$ alkyl), $-CONH_2$, $-CONR^9(C_{1-4}$ alkyl), $-CON(C_{1-4}$ alkyl$)_2$, R^8, $-OR^8$, $-COR^8$, and $-CO_2R^8$;

optionally, R^{5b} and R^{5c} together with the carbon atom to which they are attached form a 4-7 membered heterocyclic ring containing carbon atoms and 1-3 heteroatoms selected from the group consisting of NR^6, O, and $S(O)_p$; wherein said heterocycle is unsubstituted or substituted with =O.

q, at each occurrence, is selected from 0, 1, and 2; and

r, at each occurrence, is selected from 0, 1, and 2.

4. The compound of claim 3 having formula (III):



(III)

or a stereoisomer, tautomer, pharmaceutically acceptable salt thereof, wherein:

R^{1a} is selected from the group consisting of: H, halo, C_{1-2} alkyl, and methoxy;

R^{1b} is selected from the group consisting of: H and halo;

R^2 is independently selected from the group consisting of: H, F, CN, OH, C_{1-4} alkoxy, $-CHF_2$, $-CF_3$, $-OCHF_2$, $-CO(C_{1-4}$ alkyl), triazole substituted with R^{2a}, and tetrazole substituted with R^{2a};

R^3 is selected from the group consisting of: phenyl substituted with 1-2 R^{3a}, C_{3-6} cycloalkyl substituted with 1-2 R^{3a}, heterocycle substituted with 1-2 R^{3a}; wherein said heterocycle is selected from the group consisting of: piperidinyl, pyridyl, indolyl, and indazolyl.

5. A compound of claim 4 having formula (IV):



(IV)

or a stereoisomer, tautomer, pharmaceutically acceptable salt thereof, wherein:

 is selected from the group consisting of:  ,  , and 

R^3 is selected from the group consisting of: phenyl substituted with 1-2 R^{3a}, pyridyl substituted with 1-2 R^{3a}, C_{3-6} cycloalkyl substituted with 1-2 R^{3a},  , and  ;

R^7 is selected from the group consisting of: C_{1-4} alkyl.

6. The compound of claim 5 having formula (V):



(V)

or a stereoisomer, tautomer, pharmaceutically acceptable salt thereof, wherein:

R^3 is selected from the group consisting of: phenyl substituted with 1-2 R^{3a} and pyridyl substituted with 1-2 R^{3a};

 is selected from the group consisting of:  ,  ,  , and  ;

R^{3a}, at each occurrence, is selected from the group consisting of: halo, C_{1-4} alkyl, OH, C_{1-4} alkoxy, CN, NH_2, $-CO_2H$, $-CO_2(C_{1-4}$ alkyl), $-CONH_2$, $CONH(C_{1-4}$ alkyl), $-CON(C_{1-4}$ alkyl$)_2$; , $-NHCO_2(C_{1-4}$ alkyl), R^f, $-CONHR^f$, and $-CO_2R^f$;

R^{5b} and R^{5c} are independently selected from the group consisting of: H, C_{1-4} alkyl, OH, CN, NH_2, -N(C_{1-4} alkyl)$_2$, C_{1-4} alkoxy, -OCO-C_{1-4} alkyl, -CO_2H, -CO_2(C_{1-4} alkyl), -$CONH_2$, -$CONR^9$(C_{1-4} alkyl), -CON(C_{1-4} alkyl)$_2$, R^8, -OR^8, -COR^8, and -CO_2R^8;

optionally, R^{5b} and R^{5c} together with the carbon atom to which they are both attached form a 5-6 membered heterocyclic ring containing carbon atoms and 1-3 heteroatoms selected from the group consisting of NR^6, O, and $S(O)_p$; wherein said heterocycle is unsubstituted or substituted with =O; and

R^6 is selected from the group consisting of: H, C_{1-4} alkyl, -CO_2(C_{1-4} alkyl), -CO(C_{1-4} alkyl), -CO-C_{1-4} alkylene-N(C_{1-4} alkyl)$_2$, -$CONH_2$, -$(CH_2)_2$N(C_{1-4} alkyl)$_2$, -CONH(C_{1-4} alkyl), -CONH-C_{1-4} alkylene-O(C_{1-4} alkyl), -CONH-C_{1-4} alkylene-N(C_{1-4} alkyl)$_2$, -CONH-C_{1-4} alkylene-CO_2(C_{1-4} alkyl), -CON(C_{1-4} alkyl)$_2$, R^8, -COR^8, and -CO_2R^8.

7. The compound of claim 6, having formula (VI):



(VI)

or a stereoisomer, tautomer, pharmaceutically acceptable salt thereof, wherein:

R^{1b} is independently selected from the group consisting of: H and F;

R^{3a} is selected from the group consisting of: halo, CN, CO_2H, -CO_2(C_{1-4} alkyl), -$CONH_2$, -CONH(C_{1-4}alkyl), -NHCO_2(C_{1-4}alkyl), -CO_2(C_{3-6}cycloalkyl), -CO_2(CH_2)$_{1-2}$Ph, and -$CO_2(CH_2)_{1-2}$triazole.

8. The compound of claim 7, wherein:



is selected from the group consisting of :,



,



, ,



,



,



,



,



,



,



,



,



,



,



,



,



,



,



,



,



,



,



,



,



,



,



,



,



,



,



,



,



,



,



,



,



R^{3a} is independently selected from the group consisting of: F, Cl, CN, CO_2H, $-CO_2Me$, $-CO_2Et$, $-CO_2(i\text{-Pr})$, $-CO_2(t\text{-Bu})$, $-CO_2(n\text{-Bu})$, $-CO_2(i\text{-Bu})$, $-NHCO_2Me$, $-CO_2CH_2(phenyl)$, $-CO_2(C_{3\text{-}6}$ cycloalkyl), and $-CO_2(CH_2)_2$-triazole; and

R^6 is selected from the group consisting of: H, $C_{1\text{-}4}$ alkyl, $-CO_2(C_{1\text{-}4}$ alkyl), $-CO(C_{1\text{-}4}$ alkyl), $-COCH_2N(C_{1\text{-}4}$ alkyl)$_2$, $-(CH_2)_2N(C_{1\text{-}4}$ alkyl)$_2$, $-CONH(C_{1\text{-}4}$ alkyl), $-CONH-C_{1\text{-}4}$ alkylene-$O(C_{1\text{-}4}$ alkyl), $-CONH-C_{1\text{-}4}$ alkylene-$N(C_{1\text{-}4}$ alkyl)$_2$, $-CONH-C_{1\text{-}4}$ alkylene-$CO_2(C_{1\text{-}4}$ alkyl), $-CH_2Ph$, and $-CO_2-C_{1\text{-}4}$ alkylene-Ph.

9. The compound of claim 3 having Formula (VII):



(VII)

or a stereoisomer, tautomer, pharmaceutically acceptable salt thereof, wherein:

R^{1b} is selected from the group consisting of: H and F;

 is selected from the group consisting of: 





and ;

R^2 is selected from the group consisting of: H, F, CN, COMe, OH, OMe, $OCHF_2$, CHF_2, CF_3, and tetrazole;

R^3 is selected from the group consisting of: phenyl substituted with 1-2 R^{3a},



cyclohexyl, , and ;

R^{3a} is independently selected from the group consisting of: F, Cl, CN, CO_2H, $-CO_2Me$, $-CO_2Et$, $-CO_2(i\text{-Pr})$, $-CO_2(t\text{-Bu})$, $-CO_2(n\text{-Bu})$, $-CO_2(i\text{-Bu})$, $-NHCO_2Me$, $-CO_2(CH_2)_2$-triazole, and $-CO_2$(cyclopentyl);

R^{4c} and R^{4d} are independently selected from the group consisting of: H and Me;

R^{5b} and R^{5c} are, independently selected from the group consisting of: H, F, Me, Et, i-propyl, CN, OH, -OMe, $-CO_2Me$, $-CO_2Et$, $-CON(Me)_2$, NH_2, $-N(Me)_2$, $-O(CH_2)N(Me)_2$, $-O(CH_2)OMe$,





, and ;

R^6 is selected from the group consisting of: H, Me, -CO_2Me, -CO_2(t-butyl), -COMe, -CONHMe, -CONH$(CH_2)_2CO_2$Et, CONH$(CH_2)_2$N$(Me)_2$, -CO_2CH_2Ph, -$(CH_2)_2$N$(Me)_2$, and -CH_2Ph;

R^7 is selected from the group consisting of: Me;

q, at each occurrence, is selected from 0, 1, and 2; and

r, at each occurrence, is selected from 0, 1, and 2.

10. The compound of claim 9 having Formula (VIII):



(VIII)

or a stereoisomer, tautomer, pharmaceutically acceptable salt thereof, wherein:

R^2 is selected from the group consisting of: H, F, CN, COMe, OH, OMe, $OCHF_2$, CHF_2, CF_3, and tetrazole;

R^{3a} is selected from the group consisting of: F, Cl, CN, CO_2H, CO_2Me, -CO_2Et, -CO_2(*i*-Pr), -CO_2(*t*-Bu), -CO_2(*n*-Bu), -CO_2(*i*-Bu), and -NHCO_2Me;

R^6 is selected from the group consisting of: H, Me, -CO_2Me, -CO_2(t-butyl), -COMe, and –CONHMe;

q is 1or 2; and

r is 1 or 2.

11. The compound of claim 1 having formula (IX):



(IX)

or a stereoisomer, tautomer, pharmaceutically acceptable salt thereof, wherein:

R^{1a} is selected from the group consisting of: H, Cl, C_{1-2} alkyl, and methoxy;

R^{1b} is selected from the group consisting of: H and F;

R^6 is selected from the group consisting of: H, C_{1-4} alkyl, -CO(C_{1-4} alkyl), CO_2H, -CO_2(C_{1-4} alkyl), -CONH(C_{1-4} alkyl), and -CO$(CH_2)_{0-2}$N(C_{1-4} alkyl)$_2$; and

R^{3a} is selected from the group consisting of: F, Cl, CN, CO_2H, -CO_2Et, and -CO_2(*t*-Bu).

12. The compound of claim 1, wherein:

ring B is heteroaryl or bridged heterocycle, each containing carbon atoms and 0-2 additional heteroatoms selected from the group consisting of N, NH, O, and $S(O)_p$, and each substituted with 1-3 R^5;

R^2 is selected from the group consisting of: H, F, CN, -CO(C_{1-4} alkyl), OH, -O(C_{1-4} alkyl), -$OCHF_2$, -CHF_2, -CF_3, triazole, and tetrazole, wherein said triazole and tetrazole are substituted with 0-2 R^{2a}; and

R^5, at each occurrence, is selected from the group consisting of: H, =O, halo, C_{1-4} alkyl, OH, CN, NH_2, -N(C_{1-4} alkyl)$_2$, C_{1-4} alkoxy, -CO_2H, -CO_2(C_{1-4} alkyl), -$CONH_2$, -$CONR^9$(C_{1-4} alkyl), -CON(C_{1-4} alkyl)$_2$, R^8, and -COR^8.

13. A compound according to claim 1 or a stereoisomer, tautomer, pharmaceutically acceptable salt or solvate thereof, wherein the compound is selected from



wherein R, R' and R'' are:

R	R'	R"
H	Piperazine	
F	Piperazine	
F	Piperazine	
F	Piperazine	
F	Piperazine	
F	Piperazine	
F	Piperazine	
F	Piperazine	6-indazole-1-CBz

R	R'	R"
F	Boc-piperazine	6-indazole-1-*t*Boc
F	Piperazine	6-indazole



wherein R and R' are:

Stereochemistry	R	R'
R enantiomer	2-F	
S enantiomer	2-F	
S enantiomer	4-F	6-indazole
R enantiomer	4-F	6-indazole
R enantiomer	4-F	
S enantiomer	4-F	



wherein R, R' and R'' are:

R	R'	R"
F	-4-PhCOOH	CH_3
H	-4-PhNHCOO CH_3	CH_3
F	-4-PhCN	CH_3
H	-4-PhCOOH	
H	-4-PhCOOH	CH_3OOC-
H	-4-PhNHCOO CH_3	
F	-4-PhNHCOO CH_3	CH_3OOC-
F	-4-PhF	CH_3OOC-
F	-4-PhCN	CH_3OOC-
F	6-indazole	CH_3



wherein R' is

R'	Stereochemistry
COOEt	R-enantiomer
COOEt	S-enantiomer
COOH	R-enantiomer
COOH	S-enantiomer



wherein R, R' and R'' are:

Stereochemistry	R	R'	R"
Racemic	tetrazole	2-F	COOH
S-enantiomer	tetrazole	2-F	COOH
R-enantiomer	tetrazole	2-F	COOH
S-enantiomer	tetrazole	2-F	COO*t*Bu
Racemic	-COMe	2-F	COOH
R-enantiomer	-COMe	2-F	COOH
S-enantiomer	-COMe	2-F	COOH
R-enantiomer	tetrazole	4-F	COOH
S-enantiomer	tetrazole	4-F	COOH
Racemic	tetrazole	2-F	COOEt
R-enantiomer	tetrazole	2-F	COOEt
S-enantiomer	tetrazole	2-F	COOEt



wherein R and R' are:

Stereochemistry	R	R'
Racemic		-4-PhCOOH
Racemic		
R-enantiomer		-4-PhCOOH
S-enantiomer		-4-PhCOOH
S-enantiomer		-4-PhCOOtBu
Racemic		-4-PhCOOEt
Racemic		-4-PhCOOH
Racemic		

Stereochemistry	R	R'
Racemic		-4-PhCOOH
Racemic		-4-PhCOOtBu
Racemic		-4-PhCOOEt
Racemic		-4-PhCOOtBu
Racemic		-4-PhNHCOOCH$_3$
Racemic		-4-PhCOOtBu
Racemic		4-PhCOOH
R-enantiomer		4-PhCOOH
S-enantiomer		4-PhCOOH
Racemic		-4-PhCOOEt
Diastereomer		4-PhCOOH



wherein R is selected from:

R
Cyclopropanamine
2-(1*H*-imidazol-4-yl)ethanamine
Aniline
N-(4-aminophenyl)acetamide
Ethyl
N-(2-aminoethyl)acetamide
3-aminopropanamide
methyl 2-aminoacetate
3-methoxyaniline
Dimethylamine
Methylamine



wherein R and R' are:

Stereochemistry	R	R'
Racemic		-4-PhCOOH
Racemic		-4-Ph-F
Racemic		-4-PhCOOEt
Racemic		-4-PhCOOtBu
Racemic		4-PhCN
S-enantiomer		-4-Ph-F
S-enantiomer		-4-PhCOOH
R-enantiomer		-4-PhCOOH

Stereochemistry	R	R'
Racemic		-4-PhNHCOOCH$_3$
R-enantiomer		-4-Ph-F
Racemic		-4-PhCOOtBu
Racemic		-4-PhCOOH
R-enantiomer		-4-Ph-COOEt
S-enantiomer		-4-Ph-COOEt
Racemic		-4-PhCOOH
Racemic		-4-PhCOOH
Racemic		-4-PhCOOH

Stereochemistry	R	R'
R-enantiomer		-4-PhNHCOOCH$_3$
S-enantiomer		-4-PhNHCOOCH$_3$
Racemic		-4-PhCOOH
S-enantiomer		-4-PhCOOH
R-enantiomer		-4-PhCOOH
S-enantiomer		-4-PhCOOH
Racemic		-4-Ph-Cl
Racemic		-4-PhCOOnBu

Stereochemistry	R	R'
Racemic		-4-PhCOOH
R-enantiomer		-4-PhCOOH
S-enantiomer		-4-PhCOOH
Racemic		-4-PhCOOEt
S-enantiomer		-4-PhCOOEt
R-enantiomer		-4-Ph-Cl
S-enantiomer		-4-Ph-Cl
R-enantiomer		-4-PhCOOnBu
S-enantiomer		-4-PhCOOnBu

Stereochemistry	R	R'
Racemic		-4-PhCOOH
Racemic		-4-PhCOOH
Racemic		4-PhCOOH
R-enantiomer		-4-PhCOOH
S-enantiomer		-4-PhCOOH
Racemic		
Racemic		-4-PhCOOH
Racemic		-4-PhCOOiPr

Stereochemistry	R	R'
Racemic		-4-PhCOOiBu
Racemic		
R-enantiomer		-4-Ph-COOEt
S-enantiomer		-4-Ph-COOEt
Racemic		
R-enantiomer		-4-PhCOOEt
S-enantiomer		-4-PhCOOEt
Racemic		-4-PhCOOH

Stereochemistry	R	R'
Racemic		-4-PhCOOH
R-enantiomer		-4-PhCOOH
S-enantiomer		-4-PhCOOH
Racemic		-4-PhCOOEt
S-enantiomer		-4-PhCOOEt
Racemic		-4-PhCOOH
Racemic		-4-PhCOOH

Stereochemistry	R	R'
Racemic		-4-PhCOOH
S-enantiomer		-4-PhCOOH
Racemic		-4-PhCOOH
S-enantiomer		-4-PhCOOH
Racemic		-4-PhCOOH
S-enantiomer		-4-PhCOOH
S-enantiomer		-4-PhCOOMe
Racemic		-4-PhCOOH

Stereochemistry	R	R'
Racemic		-4-PhCOOH
Racemic		-4-PhCOOH
Racemic		-4-PhCOOH
S-enantiomer		-4-PhCOOH
Racemic		-4-PhCOOH
S-enantiomer		-4-PhCOOH
Racemic		-4-PhCOOH



wherein R and R' are:

Stereochemistry	R	R'
Racemic		-4-PhCOOtBu
Racemic		-4-PhCOOH
Racemic		-4-PhCOOH
Racemic		-4-PhCOOH
Racemic		-4-PhCOOH
Racemic		-4-PhCOOH
Racemic		-4-PhCOOH
Racemic		-4-PhCOOEt

Stereochemistry	R	R'
Racemic		-4-PhCOOH
Racemic		-4-PhCOOH
R-enantiomer		-4-PhCOOH
S-enantiomer		-4-PhCOOH
Racemic		-4-PhCOOEt
S-enantiomer		-4-PhCOOEt
R-enantiomer		-4-PhCOOH
S-enantiomer		-4-PhCOOH

Stereochemistry	R	R'
R-enantiomer		-4-PhCOOEt
S-enantiomer		-4-PhCOOEt
S-enantiomer		-4-PhCOOBzl
S-enantiomer		
Racemic		-4-PhCOOCH$_3$
Racemic		-4-PhCOOH
S-enantiomer		-4-PhCOOEt
S-enantiomer		-4-PhCOOH

Stereochemistry	R	R'
R-enantiomer		-4-PhCOOH
Racemic		-4-PhCOOH
Racemic		-4-PhCOOH
Racemic		-4-PhCOOH



wherein R and R' are:

Stereochemistry	R	R'
S-enantiomer		-COOEt
R-enantiomer		-COOEt
R-enantiomer		-COOH

Stereochemistry	R	R'
S-enantiomer		-COOH
R-enantiomer		-COOEt
S-enantiomer		-COOEt



wherein R and R' are:

Stereochemistry	R	R'
S-enantiomer		-COOH
R-enantiomer		-COOH
S-enantiomer		-COOEt
R-enantiomer		-COOEt
S-enantiomer		-COOH
R-enantiomer		-COOH

Stereochemistry	R	R'
S-enantiomer		-COOH
R-enantiomer		-COOH
S-enantiomer		-COOEt
S-enantiomer		-COOH
R-enantiomer		-COOH



wherein R and R' are:

Stereochemistry	R	R'
Racemic		-4-PhCOOH
S-enantiomer		-4-PhCOOH

Stereochemistry	R	R'
Racemic		-4-PhCOOH
S-enantiomer		-4-PhCOOH



wherein R, R' and R'' are:

Stereochemistry	R	R'	R''
Racemic			-4-PhCOOH
R-enantiomer			-4-PhCOOH
S-enantiomer			-4-PhCOOH

Stereochemistry	R	R'	R"
Racemic			-4-PhCOOH
S-enantiomer			-4-PhCOOH
Racemic			-4-PhCOOH
R-enantiomer			-4-PhCOOH
S-enantiomer			-4-PhCOOH
Racemic			-4-PhCOOH
Racemic			-4-PhCOOH

Stereochemistry	R	R'	R"
Racemic			-4-PhCOOH
Racemic			-4-PhCOOEt
Racemic			-4-PhCOOH
Racemic			-4-PhCOOH



wherein R is selected from:

Stereochemistry	R

Racemic	
Racemic	
Racemic	
Racemic	
Racemic	
Racemic	
Racemic	
Racemic	
Racemic	
Racemic	
Racemic	
Racemic	
Racemic	
Racemic	
Racemic	



wherein R is selected from:

Stereochemistry	R
Diastereomer	
Diastereomer	
Diastereomer	
Diastereomer	
Diastereomer	
Diastereomer	
Diastereomer	

Diastereomer	
Diastereomer	
Racemate	



wherein R and R' are:

Stereochemistry	R	R'
S-enantiomer		4-PhCOOEt
S-enantiomer		4-PhCOOH
Racemic		



wherein R and R' are:

Stereochemistry	R	R'
Racemic		4-PhCOOH
Racemic		4-PhCOOtBu
Racemic		4-PhCOOH
Racemic		4-PhCOOH
S-enantiomer		4-PhCOOH
Racemic		4-PhCOOH
Racemic		4-PhCOOH
Racemic		4-PhCOOH

Stereochemistry	R	R'
Racemic		4-PhCOOH
S-enantiomer		4-PhCOOH
S-enantiomer		4-PhCOOH



wherein R and R' are:

Stereochemistry	R	R'
S-enantiomer		
S-enantiomer		
Racemic		

Stereochemistry	R	R'
S-enantiomer		

(E)-4-(2-(3-(5-chloro-2-(1*H*-tetrazol-1-yl)phenyl)acryloyl)-5-(piperazin-1-yl)-1,2,3,4-tetrahydroisoquinoline-1-carboxamido)benzoic acid;

(E)-4-(2-(3-(2-(aminomethyl)-5-chlorophenyl)acryloyl)-5-(piperazin-1-yl)-1,2,3,4-tetrahydroisoquinoline-1-carboxamido)benzoic acid;

(E)-4-(2-(3-(5-chloro-2-(1*H*-tetrazol-1-yl)phenyl)acryloyl)-5-(2-oxopiperidin-1-yl)-1,2,3,4-tetrahydroisoquinoline-1-carboxamido)benzoic acid;

(E)-4-(2-(3-(5-chloro-4-fluoro-2-(1*H*-tetrazol-1-yl)phenyl)acryloyl)-5-(piperazin-1-yl)-1,2,3,4-tetrahydroisoquinoline-1-carboxamido)benzoic acid;

(E)-N-(4-carbamoylphenyl)-2-(3-(5-chloro-4-fluoro-2-(1*H*-tetrazol-1-yl)phenyl)acryloyl)-5-(piperazin-1-yl)-1,2,3,4-tetrahydroisoquinoline-1-carboxamide;

(E)-4-(2-(3-(3-chloro-2-fluoro-6-(1*H*-tetrazol-1-yl)phenyl)acryloyl)-3,3-dimethyl-5-(piperazin-1-yl)-1,2,3,4-tetrahydroisoquinoline-1-carboxamido)benzoic acid;

(E)-4-(2-(3-(6-acetyl-3-chloro-2-fluorophenyl)acryloyl)-5-(4-methylpiperazin-1-yl)-1,2,3,4-tetrahydroisoquinoline-1-carboxamido)benzoic acid;

(E)-4-(2-(3-(3-chloro-2-fluoro-6-(1*H*-tetrazol-1-yl)phenyl)acryloyl)-5-(4-(pyrrolidin-1-yl)piperidin-1-yl)-1,2,3,4-tetrahydroisoquinoline-1-carboxamido)benzoic acid;

(R,E)-4-(2-(3-(3-chloro-2-fluoro-6-(1H-tetrazol-1-yl)phenyl)acryloyl)-5-(4-methyl-2-oxopiperazin-1-yl)-1,2,3,4-tetrahydroisoquinoline-1-carboxamido)benzoic acid;

(S,E)-4-(2-(3-(3-chloro-2-fluoro-6-(1H-tetrazol-1-yl)phenyl)acryloyl)-5-(4-methyl-2-oxopiperazin-1-yl)-1,2,3,4-tetrahydroisoquinoline-1-carboxamido)benzoic acid;

(R,E)-ethyl 4-(2-(3-(3-chloro-2-fluoro-6-(1*H*-tetrazol-1-yl)phenyl)acryloyl)-5-(4-methyl-2-oxopiperazin-1-yl)-1,2,3,4-tetrahydroisoquinoline-1-carboxamido)benzoate;

(S,E)-ethyl 4-(2-(3-(3-chloro-2-fluoro-6-(1*H*-tetrazol-1-yl)phenyl)acryloyl)-5

-(4-methyl-2-oxopiperazin-1-yl)-1,2,3,4-tetrahydroisoquinoline-1-carboxamido)benzoate;

(R,E)-4-(2-(3-(3-chloro-2-fluoro-6-(1*H*-tetrazol-1-yl)phenyl)acryloyl)-3,3-dimethyl-5-(piperazin-1-yl)-1,2,3,4-tetrahydroisoquinoline-1-carboxamido) benzoic acid;

(S,E)-4-(2-(3-(3-chloro-2-fluoro-6-(1*H*-tetrazol-1-yl)phenyl)acryloyl)-3,3-dimethyl-5-(piperazin-1-yl)-1,2,3,4-tetrahydroisoquinoline-1-carboxamido) benzoic acid;

4-((S)-2-((E)-3-(3-chloro-2-fluoro-6-(1*H*-tetrazol-1-yl)phenyl)acryloyl)-5-((S)-3-(dimethylamino)pyrrolidin-1-yl)-1,2,3,4-tetrahydroisoquinoline-1-carboxamido)benzoic acid;

tert-butyl 4-((S)-2-((E)-3-(3-chloro-2-fluoro-6-(1*H*-tetrazol-1-yl)phenyl)acryloyl)-5-((S)-3-(dimethylamino)pyrrolidin-1-yl)-1,2,3,4-tetrahydroisoquinoline-1-carboxamido)benzoate;

4-((R)-2-((E)-3-(3-chloro-2-fluoro-6-(1*H*-tetrazol-1-yl)phenyl)acryloyl)-5-((S)-3-(dimethylamino)pyrrolidin-1-yl)-1,2,3,4-tetrahydroisoquinoline-1-carboxamido)benzoic acid;

4-((R)-2-((E)-3-(3-chloro-2-fluoro-6-(1*H*-tetrazol-1-yl)phenyl)acryloyl)-5-((R)-3-(dimethylamino)pyrrolidin-1-yl)-1,2,3,4-tetrahydroisoquinoline-1-carboxamido)benzoic acid;

4-((S)-2-((E)-3-(3-chloro-2-fluoro-6-(1*H*-tetrazol-1-yl)phenyl)acryloyl)-5-((R)-3-(dimethylamino)pyrrolidin-1-yl)-1,2,3,4-tetrahydroisoquinoline-1-carboxamido)benzoic acid;

(E)-4-(2-(3-(3-chloro-2-fluoro-6-(1*H*-tetrazol-1-yl)phenyl)acryloyl)-5-(3-(ethoxycarbonyl)-5-methyl-1*H*-pyrazol-1-yl)-1,2,3,4-tetrahydroisoquinoline-1-carboxamido)benzoic acid; and

(E)-ethyl 1-(2-(3-(3-chloro-2-fluoro-6-(1*H*-tetrazol-1-yl)phenyl)acryloyl)-1-(4-fluorophenylcarbamoyl)-1,2,3,4-tetrahydroisoquinolin-5-yl)-5-methyl-1*H*-pyrazole-3-carboxylate.

14. A compound according to claim 13 or a stereoisomer, tautomer, pharmaceutically acceptable salt or solvate thereof, wherein the compound is



15. A pharmaceutical composition, comprising: a pharmaceutically acceptable carrier and a therapeutically effective amount of a compound of any one of claims 1-14.

16. A compound of any one of claims 1-14 or a stereoisomer, tautomer, pharmaceutically acceptable salt or solvate form thereof, for use in therapy.

17. A compound of any one of claims 1-14 or a stereoisomer, tautomer, pharmaceutically acceptable salt or solvate form thereof for use in treating a thromboembolic disorder, preferably wherein the thromboembolic disorder is selected from the group consisting of arterial cardiovascular thromboembolic disorders, venous cardiovascular thromboembolic disorders, and thromboembolic disorders in the chambers of the heart, or wherein the thromboembolic disorder is selected from unstable angina, an acute coronary syndrome, atrial fibrillation, first myocardial infarction, recurrent myocardial infarction, ischemic sudden death, transient ischemic attack, stroke, atherosclerosis, peripheral occlusive arterial disease, venous thrombosis, deep vein thrombosis, thrombophlebitis, arterial embolism, coronary arterial thrombosis, cerebral arterial thrombosis, cerebral embolism, kidney embolism, pulmonary embolism, and thrombosis resulting from (a) prosthetic valves or other implants, (b) indwelling catheters, (c) stents, (d) cardiopulmonary bypass, (e) hemodialysis, or (f) other procedures in which blood is exposed to an artificial surface that promotes thrombosis.